<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03425539</url>
  </required_header>
  <id_info>
    <org_study_id>ID-069A301</org_study_id>
    <nct_id>NCT03425539</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease</brief_title>
  <acronym>MODIFY</acronym>
  <official_title>A Multicenter, dOuble-blind, ranDomized, Placebo-controlled, Parallel-group Study to Determine the effIcacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With FabrY Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Idorsia Pharmaceuticals Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Idorsia Pharmaceuticals Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aimed to determine the efficacy and safety of lucerastat oral monotherapy in adult
      subjects with Fabry disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this prospective, multicenter, double-blind, randomized,
      placebo-controlled, parallel group, Phase 3 study is to determine the effect of oral
      lucerastat monotherapy on neuropathic pain in subjects with Fabry disease (FD) through daily
      collection of patient-reported outcomes with an electronic diary.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 3, 2018</start_date>
  <completion_date type="Anticipated">November 15, 2019</completion_date>
  <primary_completion_date type="Anticipated">November 8, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response to study treatment on neuropathic pain defined as a reduction from baseline to Month 6 of at least 30% in the &quot;modified&quot; Brief Pain Inventory-Short Form 3 (BPI-SF3) score of &quot;neuropathic pain at its worst in the last 24 hours&quot;</measure>
    <time_frame>From baseline to Month 6 (duration: 6 months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Month 6 in the average daily 11-point Numerical Rating Scale (NRS-11) score of &quot;abdominal pain at its worst in the last 24 hours&quot; in subjects with GI symptoms at baseline.</measure>
    <time_frame>From baseline to Month 6 (duration: 6 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Month 6 in the number of days with at least one stool of a Bristol Stool Scale (BSS) consistency Type 6 or 7 in subjects with GI symptoms at baseline.</measure>
    <time_frame>From baseline to Month 6 (duration: 6 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Month 6 in plasma globotriaosylceramide (Gb3).</measure>
    <time_frame>From baseline to Month 6 (duration: 6 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Fabry Disease</condition>
  <arm_group>
    <arm_group_label>Lucerastat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lucerastat</intervention_name>
    <description>Hard gelatin capsules containing 250 mg of lucerastat and inactive excipients; 1000 mg (4 capsules) b.i.d.; dose adjusted for renal function.</description>
    <arm_group_label>Lucerastat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules are identical in appearance to the lucerastat capsules, and contain inactive excipients; 4 capsules b.i.d.; dose adjusted for renal function.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed and dated ICF prior to any study-mandated procedure;

          2. Male or female adult subjects;

          3. FD diagnosis confirmed with local genetic test results;

          4. Fabry-associated neuropathic pain, as defined by the subject, in the last 3 months
             prior to screening;

          5. Enzyme replacement therapy (ERT) status:

               1. Subject never treated with ERT; or

               2. Subject has not received ERT for at least 6 months prior to screening; or

               3. Subject treated with ERT since at least 12 months at the time of the screening
                  visit, and agreeing to stop ERT for approximately 8 months.

          6. A woman of childbearing potential is eligible only under certain conditions, e.g.
             taking contraceptive measures.

          7. Subjects with moderate or severe neuropathic pain during the screening period.

        Exclusion Criteria:

          1. Pregnant, planning to be become pregnant, or lactating subject.

          2. Severe renal insufficiency (eGFR &lt; 30 mL/min/1.73 m2) at screening.

          3. Subject on regular dialysis for the treatment of chronic kidney disease.

          4. Known and documented transient ischemic attack, stroke, unstable angina, or myocardial
             infarction within 6 months prior to screening.

          5. Clinically significant unstable cardiac disease (e.g. uncontrolled symptomatic
             arrhythmia, congestive heart failure NYHA class III or IV).

          6. Any known factor or disease that might interfere with treatment compliance, study
             conduct or interpretation of the results.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabrice Kramer, MD</last_name>
    <role>Study Director</role>
    <affiliation>Idorsia Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fabrice Kramer, MD</last_name>
    <phone>+41 58 844 00 00</phone>
    <email>trial.modify@idorsia.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric Wallace, Prof.</last_name>
      <email>ericlwallace@uab.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92696</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Virginia Kimonis, Dr.</last_name>
      <email>vkimonis@uci.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Florida College of Medicine</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>John Bernat, Prof.</last_name>
      <email>john-bernat@uiowa.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center - Department of Neurology</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ahmad Tuffaha, Dr.</last_name>
      <email>atuffaha@kumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Minnesota - Pediatric Gene Therapy</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chester Whitley, Prof.</last_name>
      <email>whitley@umn.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robert Hopkin, Prof.</last_name>
      <email>rob.hopkin@cchmc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh (UPMC)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Damara Ortiz, Dr.</last_name>
      <email>damara.ortiz@chp.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Baylor Institute of Metabolic Disease</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Raphael Schiffmann, Dr.</last_name>
      <email>raphael.schiffmann@bswhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicola Longo, Prof.</last_name>
      <email>nicola.longo@hsc.utah.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lysosomal and Rare Disorders Research and Treatment Center</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ozlem Goker-Alpan, Dr.</last_name>
      <email>ogoker-alpan@ldrtc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allgemeines Krankenhaus der Stadt Wien - Universitätsklinik für Innere Medizin III - Klinische Abteilung für Nephrologie und Dialyse</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alberta Children's Hospital</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3B 6A8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aneal Khan, Dr.</last_name>
      <email>khaa@ucalgary.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Health Sciences Center Halifax Infirmary - Division of Neurosurgery</name>
      <address>
        <city>Halifax</city>
        <zip>B3H 3A7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael West, Prof.</last_name>
    </contact>
    <contact_backup>
      <email>MLWEST@dal.ca</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Vancouver Hospital &amp; Health Sciences - Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sandra Sirrs, Prof.</last_name>
      <email>sandra.sirrs@vch.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Health Sciences Center Winnipeg</name>
      <address>
        <city>Winnipeg</city>
        <zip>R3A 1S1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cheryl Greenberg, Prof.</last_name>
      <email>cgreenberg@hsc.mb.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Charles University</name>
      <address>
        <city>Praha</city>
        <zip>128 08</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ales Linhart, Prof.</last_name>
      <email>ales.linhart@lf1.cuni.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Université de Versailles - Saint Quentin en Yvelines</name>
      <address>
        <city>Garches</city>
        <zip>92380</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dominique Germain, Prof.</last_name>
      <email>dominique.germain@rpc.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charite Campus Virchow-Klinikum - Nephrologie und Internistische Intensivmedizin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sima Canaan-Kühl, Dr.</last_name>
      <email>sima.canaan-kuehl@charite.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fachinternistische Gemeinschaftspraxis Markgräferland</name>
      <address>
        <city>Mühlheim</city>
        <zip>79379</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marcus Cybulla, Dr.</last_name>
      <email>dr.cybulla@f-g-m.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik und Poliklinik I der Universität Schwerpunkt Nephrologie</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter Nordbeck, Dr</last_name>
      <email>nordbeck_p@ukw.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>22660</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carla Hollak, Prof.</last_name>
      <email>c.e.hollak@amc.uva.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Birmingham NHS Foundation Trust</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2WB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tarekegn Hiwot, Dr.</last_name>
      <email>tarekegn.geberhiwot@uhb.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lysosomal Storage Disorders Unit, Department of Hematology</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Derralynn Hughes, Dr.</last_name>
      <email>derralynnhughes@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Hospital for Neurology and Neurosurgery</name>
      <address>
        <city>London</city>
        <zip>WC1N3BG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robin Lachmann, Dr.</last_name>
      <email>r.lachmann@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Endocrinology and Metabolic Medicine</name>
      <address>
        <city>Salford</city>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ana Jovanovic, Dr.</last_name>
      <email>ana.jovanovic@srft.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 16, 2018</study_first_submitted>
  <study_first_submitted_qc>February 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 7, 2018</study_first_posted>
  <last_update_submitted>April 13, 2018</last_update_submitted>
  <last_update_submitted_qc>April 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fabry Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

